Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8 % of Poseida and to receive a right of exclusive